Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Endoscopic Injection of Bulking Agents for the Treatment of Vesicoureteral Reflux and Introducing a New Material: Acellular Lyophilized Prepuce As a Natural Scaffold Publisher



Mohseni MJ1 ; Shojaie L1, 2 ; Zolbin MM1 ; Mohseni A3 ; Amirzargar H1 ; Hekmati P1 ; Kajbafzadeh AM1 ; Arshadi H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Section of Tissue Engineering and Stem Cells Therapy, Pediatric Urology and Regenerative Medicine Research Center, Children’s Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medicine, Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, United States
  3. 3. Tracheal Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Pediatrics Published:2020


Abstract

Context: Endoscopic therapy has been introduced for vesicoureteral reflux (VUR) treatment from the early 1980s and emerged as the first-line treatment in all grades of VUR. Various materials have been used for the endoscopic suburethral application, and their curative role has been characterized by different potential. In this study, we aimed to summarize the global experience with the various bulking agents used for endoscopic treatment of VUR, especially the cure and complication rates, and review our newly introduced bulking agent. Evidence Acquisition: The current literature and our experience on the outcome of endoscopic treatment with different bulking agents were reviewed. Results: Various foreign materials have been used for endoscopic suburethral injections, and their success rate has been different from 40 to ≤ 90 percent. Dextranomer/hyaluronic acid copolymer (Dx/HA), currently the most common bulking agent used for VUR resolution, is an artificial material that helps to grow collagen and fibroblasts. Activation of the immune reaction and the formation of granuloma pseudocysts are impediments after the injection of this agent. Therefore, despite the better consequences in comparison to other agents, the use of this material might be associated with the risk of appearance of serious and persistent complications. Conclusions: Our newly designed decellularized prepuce tissue as a biocompatible tissue-engineered bulking agent, is comparable to Dx/HA regarding low immunoreaction and inflammatory responses with lower price. So, it could be a proper candidate for future randomized clinical trials to investigate the potential of clinical application of the current bulking agent; moreover, it can be an appropriate alternative for Dx/HA. © 2020, Author(s).
Related Docs
1. Comparison of Polyacrylate Polyalcohol Copolymer (Ppc) and Dextranomer/Hyaluronic Acid (Dx/Ha) for Treatment of Vesicoureteral Reflux. a Systematic Review and Meta-Analysis, Journal of Pediatric Urology (2022)
2. Comparison of Histopathological Characteristics of Polyacrylate Polyalcohol Copolymer With Dextranomer/Hyaluronic Acid After Injection Beneath the Bladder Mucosa Layer: A Rabbit Model, International Urology and Nephrology (2017)
3. The Promise of Regenerative Medicine in the Treatment of Urogenital Disorders, Journal of Biomedical Materials Research - Part A (2020)
4. Endoscopic Correction of Vesicoureteral Reflux in Children With Solitary Functioning Kidney: Insertion of a Double-J Stent to Avoid Transient Ureteral Obstruction, International Urology and Nephrology (2016)
5. A Novel Endoscopic Approach for Management of Hutch Diverticulum Concomitant Vesicoureteral Reflux With Dextranomer/Hyaluronic Acid Copolymer Injection, Journal of Pediatric Urology (2023)
Experts (# of related papers)
Abdolmohammad Kajbafzadeh (3)